Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis
Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections
Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center
Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.
Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…Peri-Electrode Edema after Deep Brain Stimulation Implantation – Case Report and Literature Review
Objective: To report a case of peri-electrode edema after Deep Brain Stimulation (DBS), and discuss its main aspects. Background: PD is a neurodegenerative condition, and…Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson’s Disease
Objective: To assess the effectiveness of Bright Light Therapy (BLT) in ameliorating symptoms and neuropathology in an α-synuclein preformed fibril (α-syn PFF) induced Parkinson’s disease…LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson’s disease
Objective: We focus on the novel endogenous neural repair function that comes from the mitochondrial transfer, and we aim to elucidate the molecular mechanism by…Insulin-like growth factor 2 and inflammatory response in Parkinson Disease: Potential predictor marker
Objective: Clinical diagnosis Parkinson's disease (PD), is often difficult, with the appearance of motor symptoms hence the importance of identify non-invasive early markers is a…Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies
Objective: To develop an adeno-associated virus (AAV)-based artificial miRNA (miRNA) system targeting human α-syn. Background: Synucleinopathies such as Parkinson’s disease (PD) and Multiple System Atrophy…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.